Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Wakelee, H. A., Altorki, N. K., Zhou, C., Csoszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., Chen, Y., Chella, A., Sugawara, S., Gitlitz, B. J., Bennett, E., Wu, F., Yi, J., Deng, Y., McCleland, M., Felip, E. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.8500
View details for Web of Science ID 000708120604214